|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
17-19
|
|
pubmed:dateCreated |
2001-3-21
|
|
pubmed:abstractText |
Over 90% of cervical cancers are associated with HPV infection, the commonest being the HPV-16 subtype. Two early viral genes, E6 and 7, play major roles in the development and maintenance of the malignant phenotype. The vaccine potential of a recombinant HPV16 E7 protein was examined in two murine models of E7-expressing tumours. Formulations including the immunostimulants MPL and QS21 induced therapeutically active immune responses leading to regression of pre-established TC1 tumour lesions, associated with induction of IgG antibodies, lymphoproliferation and CTL. Our data provide a clear incentive to investigate the clinical application of this approach in cancer immunotherapy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adjuvants, Immunologic,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Viral,
http://linkedlifedata.com/resource/pubmed/chemical/Cancer Vaccines,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin G,
http://linkedlifedata.com/resource/pubmed/chemical/Oncogene Proteins, Viral,
http://linkedlifedata.com/resource/pubmed/chemical/Papillomavirus E7 Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Vaccines, Synthetic,
http://linkedlifedata.com/resource/pubmed/chemical/Viral Vaccines,
http://linkedlifedata.com/resource/pubmed/chemical/oncogene protein E7, Human...
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0264-410X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
21
|
|
pubmed:volume |
19
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2583-9
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:11257396-Adjuvants, Immunologic,
pubmed-meshheading:11257396-Animals,
pubmed-meshheading:11257396-Antibodies, Neoplasm,
pubmed-meshheading:11257396-Antibodies, Viral,
pubmed-meshheading:11257396-Cancer Vaccines,
pubmed-meshheading:11257396-Female,
pubmed-meshheading:11257396-Immunoglobulin G,
pubmed-meshheading:11257396-Lung Neoplasms,
pubmed-meshheading:11257396-Lymphocyte Activation,
pubmed-meshheading:11257396-Mice,
pubmed-meshheading:11257396-Mice, Inbred C57BL,
pubmed-meshheading:11257396-Mice, Nude,
pubmed-meshheading:11257396-Oncogene Proteins, Viral,
pubmed-meshheading:11257396-Papillomaviridae,
pubmed-meshheading:11257396-Papillomavirus E7 Proteins,
pubmed-meshheading:11257396-Papillomavirus Infections,
pubmed-meshheading:11257396-T-Lymphocytes, Cytotoxic,
pubmed-meshheading:11257396-Tumor Virus Infections,
pubmed-meshheading:11257396-Uterine Cervical Neoplasms,
pubmed-meshheading:11257396-Vaccines, Synthetic,
pubmed-meshheading:11257396-Viral Vaccines
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
Therapeutic potential of protein and adjuvant vaccinations on tumour growth.
|
|
pubmed:affiliation |
SmithKline Beecham Biologicals, R&D, Preclinical Immunology, Rue de 1'Institut 89, B-1330, Rixensart, Belgium. catherine.gerard@sbbio.be
|
|
pubmed:publicationType |
Journal Article,
In Vitro,
Research Support, Non-U.S. Gov't
|
